[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cord-blood-transplantation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cord-blood-transplantation":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100347363","cord-blood-transplantation-with-myeloablative-conditioning-and-post-transplant-cyclophosphamide-compact-study-100347363",false,"NCT03802773","Cord Blood Transplantation With Myeloablative Conditioning and Post-transplant Cyclophosphamide (COmPACt Study)","Cord Blood Transplantation With Myeloablative Conditioning and Post-transplant Cyclophosphamide in Patients With Hematological Malignancies (The COmPACt Study)","COmPACt","Inclusion Criteria:\n\n* Age: ≥ 18 ≤ 75 years old\n* CB unit transplantation (TNC\\> 2,0 x10\\^7\u002Fkg and \\> 4\u002F6 loci HLA matched)\n* Myeloablative conditioning regimen consisting of either Thiotepa\u002F Busulfan\u002F Fludarabine or TBI\u002F Fludarabine\n* GVHD prophylaxis including PT-Cy (30 mg\u002Fkg or more on days + 3and +5) CSA and MMF\n* Diagnosis of 1 of the following hematological malignancies: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, high risk Acute Lymphoblastic Leukemia (ALL), Bi phenotypic\u002Fundifferentiated leukemia, Chronic Myeloid Leukemia resistant to TK inhibitors, Ph-neg Myeloproliferative Neoplasms, resistant\u002Frelapsing Non-Hodgkin's lymphoma ineligible for an autologous transplant.\n\nExclusion Criteria:\n\n* Positive serologic markers for human immunodeficiency virus (HIV)\n* Acute hepatitis B virus (HBV) or acute hepatitis C virus (HCV) infection","ALL","18 Years","75 Years",{"count":21,"type":22},10,"ESTIMATED","OBSERVATIONAL","Despite anti-thymocyte globulin has a mainstay role in preventing GvHD (and non-relapse mortality) in CB transplantation, it also induces delayed immune recovery, increased risk of cytomegalovirus and Epstein-Barr virus reactivation, post-transplant lymphoproliferative diseases, overall accounting for increased transplant-related mortality and\u002For increased relapse incidence. All these findings support the use of alternative approaches for in vivo T cell depletion in the setting of CB transplantation.",[26,27],"Cord Blood Transplantation","Hematological Malignancies","RECRUITING","2025-04-07",{"date":31,"type":32},"2025-04-09","ACTUAL",{"date":34,"type":32},"2019-03-14",{"date":36,"type":22},"2025-12-31",{"name":38,"class":39},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":48,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":51,"conditions":52,"keywords":55,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":40},"100188430","the-collection-and-storage-of-umbilical-cord-blood-for-transplantation-100188430","NCT01728545","The Collection and Storage of Umbilical Cord Blood for Transplantation","Inclusion Criteria\n\n1. Pregnant women age 18 or older. Cord blood will not be collected from a minor.\n2. Able to give verbal informed consent prior to collection of the cord blood.\n3. Able to give written informed consent prior to collection of the cord blood.\n4. Willing to provide a personal and family medical history (if available) of herself and the biologic father (if available), prior to or following collection of the cord blood.\n5. Willing to consent to testing of her blood and the cord blood for infectious diseases, including human immunodeficiency virus (HIV), human T cell lymphotrophic virus (HTLV), hepatitis B and C, cytomegalovirus (CMV), syphilis (RPR), Trypanosoma cruzi (Chagas) and West Nile Virus (WNV). Incomplete tests or positive infectious disease testing results may result in the cord blood unit being deemed unacceptable for clinical use.\n6. Willing to consent to testing the cord blood for HLA type, ABO\u002FRhD type, newborn screening and microbial cultures.\n\nExclusion Criteria:\n\nN\u002FA",true,"FEMALE",{"count":50,"type":22},250000,"The goal of this study is to collect blood samples from the umbilical cords of newborn babies, as soon as they are delivered, and to place these samples in the MD Anderson Cord Blood Bank. Your sample may be included in the National Cord Blood Inventory (NCBI) which is part of the CW Bill Young Cell Transplantation Program. The NCBI is a federally-supported program to assist in the collection of cord blood. Cord blood will be made available to patients through The National Marrow Donor Program (NMDP). These samples may then be offered to MD Anderson and other institutions for patients who need a bone marrow transplant and do not have a donor. The MD Anderson Cord Blood Bank will have the rights to release cord blood units to these institutions around the world according to established bone marrow transplant donor criteria, for a fee to cover costs.\n\nCord blood samples that are collected and then do not meet the clinical requirements for patient use may also be used at MD Anderson or other institutions either for research or for quality purposes to improve cord blood banking procedures. If not suitable for patient use or for research purposes, the cord blood unit may be thrown away.",[53,26,54],"Cord Blood Stem Cell Transplantation","Hematopoietic Stem Cell Transplantation",[56,57,58,59,60,61,54,62,63,64,65,66,67],"Cord blood registry","Umbilical Cord Blood","fetal blood","placenta","Placental Blood Stem Cell Transplantation","hematopoietic progenitor cells","cord blood unit total nucleated cell","TNC","CD34-positive(+) cell","human leukocyte antigen","HLA","allogeneic transplantation","2019-05-10",{"date":70,"type":32},"2019-05-13",{"date":72,"type":32},"2005-04",{"date":74,"type":22},"2099-04",{"name":76,"class":39},"M.D. Anderson Cancer Center"]